590 material Form 8-K filings that 521 companies we cover made with the SEC in October 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Murphy Oil Corporation's board appointed Eric M. Hambly, currently president and chief operating officer, as president and chief executive officer, effective January 1, 2025, and elected him to the board on the same date. Roger W. Jenkins, CEO for 11 years, retires as CEO and from the board on December 31, 2024, and will serve as a non-executive advisor until December 31, 2025. The filing reports no financial results, and the company said it remains committed to its strategic priorities of Delever, Execute, Explore, Return.
Eric M. Hambly, age 50, joined Murphy in 2006 and became president and chief operating officer in February 2024.
Hambly's CEO appointment and board seat take effect January 1, 2025.
Roger W. Jenkins retires as CEO and board member on December 31, 2024, and remains an advisor until December 31, 2025.
ICU Medical's board appointed Daniel Woolson, 48, as President on September 30, 2024, effective immediately. Woolson has been Corporate Vice President and General Manager of Infusion Systems since 2017. The filing does not describe any financial impact or change to the company's outlook.
Board appointed Daniel Woolson, 48, as President on September 30, 2024, effective immediately
Woolson has served as Corporate Vice President, General Manager – Infusion Systems since 2017
Previously President, Respiratory Solutions at Becton Dickinson from March 2015 to November 2016
On October 2, 2024, Liquidia Technologies, a wholly owned subsidiary of Liquidia Corporation, amended its license with Pharmosa Biopharm to extend the rights to L606 beyond North America to markets including Europe and Japan. The companies also signed a Device License Agreement giving Liquidia exclusive rights to Pharmosa's next-generation nebulizers for use with L606 in most countries. The filing says Liquidia will pay $3.5 million upfront and up to $157.75 million in potential milestones, with royalty terms unchanged, but it does not report any revenue or profit effect.
Upfront payment of $3.5 million due within 30 days after Liquidia Technologies receives Pharmosa's invoice following the October 2, 2024 Effective Date
Up to $7.75 million in development milestones and up to $150 million in sales milestones, both tied to activity outside North America
Pharmosa retains China, Korea, Taiwan, Middle East, North Africa, Turkey and Southeast Asia; royalties on global net sales are unchanged
Full text of the First Amendment and Device License Agreement will be filed as exhibits to the next Form 10-Q
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.